Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics ...
H.C. Wainwright notes that Core Scientific’s (CORZ) stock “took a flyer” during trading yesterday on the news that its key HPC customer, ...
Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its price target upped by HC Wainwright from $200.00 to $217.00 in a ...
Fintel reports that on March 11, 2025, HC Wainwright & Co. initiated coverage of Westwater Resources (NYSEAM:WWR) with a Buy ...
H.C. Wainwright initiated coverage of Inuvo (INUV) with a Buy rating and $2 price target Inuvo utilizes its proprietary IntentKey artificial ...
Investment analysts at HC Wainwright lowered their Q1 2025 EPS estimates for EyePoint Pharmaceuticals in a research note ...
"As the market continues to grow, we believe Inuvo is well positioned given a differentiated approach which better aligns with shifting consumer demand for privacy and new regulations," Buck wrote. He ...
H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ). The total consideration of ...
Fintel reports that on March 5, 2025, HC Wainwright & Co. initiated coverage of Intellia Therapeutics (LSE:0JBU) with a Buy recommendation. There are 572 funds or institutions reporting positions ...
In a report released yesterday, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research ...
Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate ...